ArticleThe American journal of medicine1986
Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial.
Article in The American journal of medicine, 1986. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study
Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)
Mortality Surveillance of MRFIT Screenees
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Pooled it
- Central blood pressure lowering effect of telmisartan-rosuvastatin single-pill combination in hypertensive patients combined with dyslipidemia: A pilot study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Trial
- Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong).Drug design, development and therapy · 2016 · on this mapTrial
- A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia.European journal of clinical pharmacology · 1993Trial
- Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Hypoglycemic and hypolipidemic effects of unsaponifiable matter from okra seed in diabetic rats.Nutrition research and practice · 2024Article
- Hypertension and Dyslipidemia: the Two Partners in Endothelium-Related Crime.Current atherosclerosis reports · 2023Review
- Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (RovatitanDrug design, development and therapy · 2023Observational
- Metabolomic characterization of hypertension and dyslipidemia.Metabolomics : Official journal of the Metabolomic Society · 2018Article
- Practical Applications for Single Pill Combinations in the Cardiovascular Continuum.Cardiac failure review · 2017Article
- Hypercholesterolemia blunts the oxidative stress elicited by hypertension in venules through angiotensin II type-2 receptors.Microvascular research · 2016Article
- Contemporary management and attainment of cholesterol targets for patients with dyslipidemia in China.PloS one · 2013Article
- LIPITENSION: Interplay between dyslipidemia and hypertension.Indian journal of endocrinology and metabolism · 2012Article
- The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.Current cardiology reviews · 2010Article
- Simvastatin decreases endothelial progenitor cell apoptosis in the kidney of hypertensive hypercholesterolemic pigs.Arteriosclerosis, thrombosis, and vascular biology · 2010Article
- Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.Vascular health and risk management · 2008Review
- The prevalence of hypertension and its association with other cardiovascular disease risk factors in a representative sample of the Lebanese population.Journal of human hypertension · 2005Article
- Pharmacoeconomic impact of non-compliance with statins.PharmacoEconomics · 2005Review
- Hypertension and combinations of cardiovascular risk factors. An epidemiologic case-control study in an adult population in Guadeloupe (FWI).European journal of epidemiology · 2001Article
- Community control of hypertension at work-site: epidemiological data of the Agusta project.European journal of epidemiology · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the impact of serum cholesterol level on the risk of fatal coronary heart disease for men with high blood pressure, the six-year follow-up data from 361,662 men (aged 35 to 57 years) screened in 18 cities in the recruitment effort for the Multiple Risk Factor Intervention Trial were evaluated. Of these men, 356,222 reported no history of hospitalization for myocardial infarction; 100,032 of these 356,222 had a baseline mean diastolic blood pressure equal to or greater than 90 mm Hg. For those men with high blood pressure, the overall age-adjusted six-year rate of coronary heart disease death was 79 percent higher than for those with diastolic blood pressure less than 90 mm Hg. Compared with men with diastolic blood pressure less than 90 mm Hg and serum cholesterol below 182 mg/dl, men with diastolic blood pressure equal to or greater than 90 mm Hg had the following relative risks, based on the serum cholesterol level: for those with a serum cholesterol level less than 182 mg/dl, risk was 1.64; for those with a level of 182 to 202 mg/dl, risk was 2.14; for those with a level of 203 to 220 mg/dl, risk was 3.14; for those with a level of 221 to 244 mg/dl, risk was 3.29; and for those with a level equal to or greater than 245 mg/dl, risk was 5.14. Thus, for men with high blood pressure, serum cholesterol related to coronary heart disease risk in a strong, graded way, over the entire distribution of serum cholesterol, from levels of 182 mg/dl and higher. This was the case for hypertensive male smokers and nonsmokers, with cigarette use associated with a further marked increase in risk--at least a doubling of the mortality rate--at any level of serum cholesterol. These data underscore the necessity for a strategy of comprehensive care for persons with high blood pressure, including approaches to both nutritional and hygienic counseling and drug treatment, aimed at controlling all of the established major risk factors influencing prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.